Literature DB >> 3411241

Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.

N A Le1, J C Gibson, H N Ginsberg.   

Abstract

Apolipoproteins C-II (apoC-II) and C-III (apoC-III) are distributed among all the major lipoprotein classes, particularly very low density (VLDL) and high density lipoproteins (HDL). We have determined concentrations of apoC-II and apoC-III in VLDL and HDL in subjects with a wide range of VLDL triglyceride and HDL cholesterol levels, and correlated these levels with fractional catabolic rates (FCR) of VLDL triglyceride and HDL apolipoprotein A-I (apoA-I). Both apoC-II and apoC-III levels increased in VLDL as VLDL apolipoprotein B (apoB) and triglyceride levels rose. The rate of rise of VLDL apoC-III, however, was approximately 3 times greater than that of apoC-II, and positive correlations were present between the ratio of VLDL apoC-III/apoC-II and both VLDL apoB (r = 0.59; P less than 0.01) and VLDL triglyceride (r = 0.70; P less than 0.005) levels. Univariate analysis demonstrated that the FCR for VLDL triglyceride was inversely related to the ratio of apoC-III/apoC-II in VLDL (r = -0.58; P less than 0.05), although this relationship was not significant in a multivariate analysis. In HDL, concentrations of apoC-III and apoA-I were correlated (r = 0.73; P less than 0.005) while no correlation was observed between apoC-II and apoA-I levels. Univariate analyses of HDL variables revealed inverse correlations between the concentration of apoC-III and the FCR for apoA-I (r = -0.67; P less than 0.005) and between the ratio of apoC-III/apoA-I and the FCR for apoA-I (r = -0.66; P less than 0.005). Multivariate analysis confirmed the latter relationship.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411241

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver.

Authors:  Y J Wan; D An; Y Cai; J J Repa; T Hung-Po Chen; M Flores; C Postic; M A Magnuson; J Chen; K R Chien; S French; D J Mangelsdorf; H M Sucov
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

Authors:  B Lamarche; K D Uffelman; A Carpentier; J S Cohn; G Steiner; P H Barrett; G F Lewis
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.

Authors:  KyeongJin Kim; Ira J Goldberg; Mark J Graham; Meenakshi Sundaram; Enrico Bertaggia; Samuel X Lee; Li Qiang; Rebecca A Haeusler; Daniel Metzger; Pierre Chambon; Zemin Yao; Henry N Ginsberg; Utpal B Pajvani
Journal:  Cell Metab       Date:  2018-03-22       Impact factor: 27.287

5.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Authors:  T Ebara; R Ramakrishnan; G Steiner; N S Shachter
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

6.  Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element.

Authors:  P J Gruber; A Torres-Rosado; M L Wolak; T Leff
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

7.  Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

Authors:  John S Millar; Danielle Duffy; Ramprasad Gadi; LeAnne T Bloedon; Richard L Dunbar; Megan L Wolfe; Rajesh Movva; Ashish Shah; Ilia V Fuki; Mary McCoy; Cynthia J Harris; Ming-Dauh Wang; Daniel C Howey; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-06       Impact factor: 8.311

8.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

9.  Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Authors:  N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

Review 10.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.